NASDAQ$IMTX
Immatics NV · Q4 2024 earnings
Q4 2024 earnings · · Before market open · Investor relations
Briefing
Immatics swings to FY 2024 profit on $161.9M BMS collaboration termination revenue
Immatics reported full-year 2024 results on March 27, 2025, posting net profit of $15.8 million versus a $98.3 million net loss in 2023. Total collaboration revenue surged to $161.9 million from $56.1 million, driven largely by one-time revenue from Bristol Myers Squibb terminating the IMA401 and ACTallo collaborations. Research and development expenses rose to $153.9 million from $123.3 million as clinical programs advanced, while general and administrative costs increased to $48.2 million. Cash and other financial assets totaled $628.0 million at year-end, extending the company's runway into the second half of 2027 after January and October 2024 equity offerings.
- Net profit of $15.8 million in FY 2024 compared with a $98.3 million net loss in FY 2023, aided by one-time collaboration termination revenue.
- Collaboration revenue reached $161.9 million, up from $56.1 million, primarily from BMS ending the IMA401 and ACTallo programs.
- R&D spending increased to $153.9 million as SUPRAME Phase 3 for IMA203 and other TCR programs advanced.
- Cash and other financial assets of $628.0 million at December 31, 2024 support operations into 2H 2027.
- First patient randomized in the SUPRAME Phase 3 trial for lead TCR-T candidate IMA203 in advanced melanoma.
Headline financials
Revenue & EPS history
Immatics · Revenue · Quarterly
$162M
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
-0.8%
Avg return
Earnings day
-1.0%
Avg return
5 days after
+4.6%
Avg return
30 days after
46%
11 / 24 earnings
Positive
+9.1%
Q3 2020
Best reaction
-11.3%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | -5.0% | -3.3% | -9.3% | |
| Q4 2024 | -11.3% | -11.7% | -0.2% | |
| Q1 2024 | +0.7% | -0.4% | +17.7% | |
| Q4 2023 | -6.6% | -5.6% | -15.3% | |
| Q3 2023 | -6.6% | -9.2% | +2.5% | |
| Q2 2023 | +7.3% | +9.7% | +7.1% | |
| Q1 2023 | -0.7% | -2.7% | +17.8% | |
| Q4 2022 | -5.1% | -8.7% | -2.8% | |
| Q3 2022 | +2.3% | -4.0% | -12.1% | |
| Q2 2022 | -7.0% | -9.2% | +1.3% | |
| Q1 2022 | +5.8% | +10.6% | +18.0% | |
| Q4 2021 | +1.8% | +2.7% | +6.9% | |
| Q3 2021 | +2.7% | -0.3% | +1.8% | |
| Q2 2021 | -0.7% | -0.5% | +28.2% | |
| Q1 2021 | -2.7% | +2.7% | +9.5% | |
| Q4 2020 | -5.2% | -1.6% | +5.9% | |
| Q3 2020 | +9.1% | +8.8% | +9.1% | |
| Q2 2020 | +1.6% | -5.6% | +16.5% | |
| Q1 2020 | -0.5% | +0.5% | +3.6% | |
| Q4 2019 | +0.0% | +2.1% | +2.8% | |
| Q3 2019 | +0.2% | -0.3% | +0.0% | |
| Q2 2019 | -0.3% | +1.2% | -0.2% | |
| Q1 2019 | +0.1% | +0.2% | +0.0% | |
| Q4 2018 | +1.2% | +1.2% | +1.2% | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro